FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies By Ogkologos - August 12, 2026 42 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Precision-T study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Therapeutic radiography: where theory meets practice July 3, 2023 Study in India Could Make Immunotherapy More Affordable Worldwide November 22, 2022 COVID-19 Vaccines: Considerations for Special Populations February 4, 2021 Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery November 30, 2018 Load more HOT NEWS Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... ‘A significant step forwards’ – treating patients with advanced biliary tract... New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where... FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma
